

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/260536965>

# Aspects on radiolabeling of $^{177}\text{Lu}$ -DOTA-TATE: After C18 purification re-addition of ascorbic acid is required to maintain radiochemical purity

Article · February 2014

DOI: 10.5430/jjdi.v1n1p5

CITATIONS

2

READS

404

5 authors, including:



**Stephan Maus**

Universitätsklinikum des Saarlandes

61 PUBLICATIONS 202 CITATIONS

[SEE PROFILE](#)



**Erik de Blois**

Erasmus MC

84 PUBLICATIONS 1,205 CITATIONS

[SEE PROFILE](#)



**Stephan-Johann Ament**

Universitätsmedizin der Johannes Gutenberg-Universität Mainz

17 PUBLICATIONS 65 CITATIONS

[SEE PROFILE](#)



**Mathias Schreckenberger**

Universitätsmedizin der Johannes Gutenberg-Universität Mainz

290 PUBLICATIONS 5,580 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



Effectiveness of quenchers (In-111- or Lu-177 labelled peptides) [View project](#)



Radiopharmacy [View project](#)

## ORIGINAL ARTICLES

# Aspects on radiolabeling of $^{177}\text{Lu}$ -DOTA-TATE: After C18 purification re-addition of ascorbic acid is required to maintain radiochemical purity

Stephan Maus<sup>1</sup>, Erik de Blois<sup>2</sup>, Stephan J. Ament<sup>1</sup>, Mathias Schreckenberger<sup>1</sup>, Wouter A. P. Breeman<sup>2</sup>

1. Clinic of Nuclear Medicine, University Medical Centre Mainz, Langenbeckstr, Mainz, Germany. 2. Department of Nuclear Medicine, Erasmus MC Rotterdam, Rotterdam, Netherlands

**Correspondence:** Stephan Maus. Address: Klinik und Poliklinik für Nuklearmedizin Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Germany. Email: stephan.maus@unimedizin-mainz.de

**Received:** January 24, 2014

**Accepted:** February 16, 2014

**Online Published:** February 21, 2014

**DOI:** 10.5430/ijdi.v1n1p5

**URL:** <http://dx.doi.org/10.5430/ijdi.v1n1p5>

## Abstract

**Purpose:** Radiolabeled peptides like  $^{177}\text{Lu}$ -DOTA-TATE are vulnerable to radiolysis, which results in decreased radiochemical purity (RCP) of these radiopeptides. Gentisic acid (GA) and ascorbic acid (AA) are well known ingredients to reduce the effects of radiolysis. Currently, there is a trend to change the procedure from a manual to a cassette-based automated labeling and to introduce a C18 solid phase extraction (SPE) post-radiolabeling in order to remove non-incorporated  $^{177}\text{Lu}$  from the injection solution. However, with the introduction of SPE purification, GA and AA might effectively be removed from injection solution with a concordant dramatic drop of the RCP. Therefore we investigated the impact of tC18 SPE purification on the RCP of  $^{177}\text{Lu}$ -DOTA-TATE.

**Methods:** We compared the manual radiolabeling procedure with the cassette-based automated radiolabeling procedure with/out tC18 SPE purification cartridge. The effect of tC18 purification on RCP of  $^{177}\text{Lu}$ -DOTA-TATE was investigated by HPLC as function of the post-radiolabeling time and the concentration of activity.

**Results:** After tC18 SPE purification, GA and AA were effectively removed and resulted in volume-dependent decrease in RCP, e.g. <95% after 5h in 20 mL. Re-addition of AA directly after tC18 SPE purification resulted in a RCP  $\geq 95\%$  at 72h. In addition, with the cassette-based automated radiolabeling procedure we also found 28% of the original activity remaining in the activity-containing vial and tubing vs. < 1% with the manual procedure.

**Conclusion:** Re-addition of AA post tC18 SPE purification is required to maintain RCP of  $^{177}\text{Lu}$ -DOTA-TATE.

## Keywords

Lutetium-177,  $^{177}\text{Lu}$ -DOTA-TATE, Cassette-based, Automated radiolabeling, Radiochemical purity, Ascorbic acid, Quencher, Gentisic acid, Radiolysis

## 1 Introduction

Radiolabeled somatostatin analogues, such as [DOTA<sup>0</sup>,Tyr<sup>3</sup>]octreotate, further referred as DOTA-TATE have been subject of intensive research during the last 2 decades and play an important role in somatostatin receptor imaging and peptide receptor-targeted radionuclide therapy (PRRT) e.g.  $^{177}\text{Lu}$ -DOTA-TATE<sup>[1-7]</sup>.

RCP of  $^{177}\text{Lu}$ -DOTA-TATE is an essential factor for successful PRRT. Because of the high doses of  $^{177}\text{Lu}$ -DOTA-TATE (7.4 GBq  $^{177}\text{Lu}$  per PRRT administration), the peptide is subject to radiolysis. The degree of radiolysis is influenced by several factors like the amount of DOTA-TATE, temperature, time, the total activity, the volumic activity, quencher(s) et cetera [8-12].

In the current publication we present a comparative study to investigate the effect of gentisic acid (GA) and ascorbic acid (AA) as quenchers during and after (manual and cassette-based automated) the radiolabeling  $^{177}\text{Lu}$ -DOTA-TATE procedures.

There is currently a trend to move from manual radiolabeling to a cassette-based automated radiolabeling procedure; therefore we investigated these two different procedures in parallel. Sep-Pak Light tC18 SPE purification (further referred as tC18) is included as default in the cassette-based automated procedure. However, the tC18 purification of the reaction mixture after radiolabeling potentially removes GA and/or AA effectively. The aim of this study was to compare radiolabeling procedures (manual vs. cassette-based automated) with and without tC18 purification and to investigate the impact on the RCP of  $^{177}\text{Lu}$ -DOTA-TATE as function of time until the moment of administration to patient.

## Materials and chemicals

Reagents and solvents were used in the highest quality grade without further purification.

GA and water for trace analyses (Trace-SELECT®) were purchased from Sigma-Aldrich Chemie GmbH (Taufkirchen, Germany). Hydrochloric acid 30% (HCl) Ultrapur was obtained from Merck KGaA (Darmstadt, Germany). AA was purchased from WÖRWAG Pharma GmbH & Co. KG (Böblingen, Germany). DOTA-TATE as kit formulation [13] was provided by Erasmus MC Rotterdam (Rotterdam, The Netherlands). Ethanol (99.5%), Aqua ad iniectabilia and isotonic 0.9% NaCl (further referred as saline) were purchased from B.Braun Melsungen AG (Melsungen, Germany). tC18 cartridges were obtained from Waters GmbH (Eschborn, Germany).  $^{177}\text{LuCl}_3$  with specific activities in the range 740-1000 GBq/mg was bought from IDB-Holland (Baarle Nassau, the Netherlands).

## 2 General methods

The manual radiolabeling procedure was performed in a temperature-controlled heating block from CardiRad (Lohja, Finland) and cassette-based automated radiolabeling procedure was performed in a Modular-Lab Pharm Tracer module (EZAG, Berlin, Germany) using the C4-Y90-00-standard synthesis and C1-PR-00 pressure test cassette (EZAG, Berlin, Germany).

### 2.1 Cassette-based automated radiolabeling procedure

The cassette was prepared according to the Y-Lu-INCASSETTE-TEST protocol (EZAG, Berlin, Germany). For standard patient radiolabeling, 240  $\mu\text{g}$  DOTA-TATE in 0.6 mL (400  $\mu\text{g}/\text{mL}$ ) of the DOTA-TATE kit formulation [13] was transferred automatically and quantitatively in to a glass reaction vial (RV) and eventually 7.5 GBq  $^{177}\text{LuCl}_3$  (0.3 mL) was added in to RV. Subsequent program steps are consecutively executed and the radiolabeling was running automatically according to the LU-177-DOTA-PEPTIDES-PT-V.X.X protocol (according EZAG). RV was heated for 30 min at 80°C. After 5 min cooling to ambient temperature the reaction mixture was transferred from the RV to the preconditioned tC18 cartridge. Pre-conditioning of the tC18 cartridge was performed with an ethanol/water mixture (5 mL, 50:50% v/v). This tC18 procedure was introduced in order to remove non-incorporated  $^{177}\text{Lu}$  from the final product. The content of RV was transferred to the tC18 cartridge and rinsed with 3 mL saline.  $^{177}\text{Lu}$ -DOTA-TATE was desorbed from the tC18 cartridge with 2.5 mL of ethanol/water (50:50% v/v). An aliquot of the final mixture was taken and subjected to quality control by ITLC and HPLC. The eluate plus 17.5 mL saline solution (final volume 20 mL) were

filtered with means of a sterile Millex-GV 0.22  $\mu\text{m}$  filter into a 25 mL glass vial (product vial or PV). Finally, a filter integrity test was performed. The cassette-based automated radiolabeling procedure process takes about 60 min.

## 2.2 Manual radiolabeling procedure

The manual radiolabeling procedure was performed directly in the activity-containing vial (AV), containing 7.5 GBq  $^{177}\text{LuCl}_3$  in 0.3 mL. For standart patient radiolabeling 0.6 mL (240  $\mu\text{g}$  DOTA-Tate) of the DOTA-TATE kit formulation  $^{13}\text{I}$  was added to the AV, and incubated for 30 min at 80  $^\circ\text{C}$   $^{13}\text{I}$ . After cooling down to ambient temperature non-incorporated  $^{177}\text{Lu}$  was complexed by the addition of 0.25 mL DTPA-solution (4 mg/mL) to the reaction mixture  $^{14-15}\text{I}$ . An aliquot of the reaction mixture was taken and quality control was performed using ITLC and HPLC. The residual was diluted with 5 mL saline solution, filtered with means of a sterile Millex-GV 0.22  $\mu\text{m}$  filter into PV and finally adjusted to a final volume of 20 mL. The manual radiolabeling procedure takes about 40 min.

## 3 Studies on RCP of $^{177}\text{Lu}$ -DOTA-TATE

RCP is defined as the % of the activity of the radionuclide present in the desired radiopharmaceutical form of the total radioactivity. RCP of  $^{177}\text{Lu}$ -DOTA-TATE was investigated with/without tC18 purification and re-addition of quenchers as shown in experiments 1-4, see Table 1. In order to investigate the dilution of the quenchers two additional radiolabeling were performed (experiment 5-6, see Table 1). One radiolabeling included tC18 purification (experiment 5, see Table 1), while another radiolabeling (experiment 6) was performed without the tC18 purification. Both samples were diluted with saline up to a final volume of 20 mL, at constant concentration of  $\sim 0.5$  GBq/mL. In addition, experiment 7 was performed without tC18 purification post radiolabeling and was diluted to a patient dose (7.4 GBq in 100 mL). RCP was determined by HPLC, as described below.

**Table 1.** Different post radiolabeling procedures of  $^{177}\text{Lu}$ -DOTATATE

Experiment	1	2	3	4	5	6	7
tC <sub>18</sub> purification	-	+	+	+	-	+	-
Ethanol/H <sub>2</sub> O 50/50% (2.5 mL)	-	+	+	+	-	+	-
Re-addition AA or GA (100 mmol/L)	-	-	AA	GA	-	-	-
Final volume (mL)	5	5	5	5	20	20	100
Total activity (GBq)	2.5	2.5	2.5	2.5	10	10	7.4
0.5 GBq/mL	+	+	+	+	+	+	-

Labelings were performed using 7.5 GBq of  $^{177}\text{LuCl}_3$  (0.3 mL) and 0.6 mL of kit Erasmus MC matrix. Thereafter post radiolabeling procedures were performed either with/without tC18 purification, re-addition of AA or GA, and diluted in different final volumes (5, 20 and 100 mL) with saline. RCP of  $^{177}\text{Lu}$ -DOTA-TATE was monitored as function of time

## 4 Analytical methods

### 4.1 Incorporation by ITLC

ITLC-SG glass fibre sheets were purchased from PALL Life Sciences (Port Washington, NY, USA). Small portions (1-3  $\mu\text{L}$ ) were added on the ITLC-SG strips and sodium citrate buffer (0.1 M, pH 5) was used as mobile phase as described  $^{14, 16}\text{I}$ . Activity was recorded by Gina Star TLC and analyzed using Raytest miniGita software (Straubenhardt, Germany). Calculation of incorporation was performed as described  $^{16}\text{I}$ .

## 4.2 HPLC

HPLC methods were performed using a Dionex-3000 HPLC system with a variable wavelength Dionex GmbH detector (Idstein, Germany) containing a Waters 4.6 mm × 250 mm, 5µm Symmetry C18 column (Eschborn, Germany). The gradient elution system utilized mobile phase A (methanol) and mobile phase B (0.06 M sodium acetate buffer, pH 5.5). Gradient was performed with a flow rate of 1 mL/min starting with 100 % B for 6.5 min; and was changed to 50% A and 50% B within 0.5 min and increased to 60% A over 20 min.

Thereafter, the mobile phase A was increased within 0.2 min to 100 % and was kept constant for 4.8 min. Finally, the gradient parameters returned to the initial starting conditions. The data were analyzed using Chromeleon Client Software Version 6.8.9. from Dionex GmbH (Idstein, Germany).


## 5 Results

### 5.1 Radiochemical yield

With the cassette-based automated radiolabeling procedure we obtained radiochemical yields of  $71 \pm 18 \%$  (n=12). The manual labeling achieved radiochemical yields  $\geq 99\%$  (n=3), independent of activity (range 2.5-10 GBq) or final volume (range 5-20 mL).

### 5.2 Radiolabeling without tC18 Purification

RCP of  $^{177}\text{Lu}$ -DOTA-TATE was measured by HPLC up to 168 h post-radiolabeling. Fig. 1A shows a typical HPLC radiochromatogram of  $^{177}\text{Lu}$ -DOTA-TATE which was prepared as described [13]. Fig. 1B shows the HPLC radiochromatogram of  $^{177}\text{Lu}$ -DOTA-TATE in the absence of quenchers. Fig. 2A clearly demonstrates that  $^{177}\text{Lu}$ -DOTA-TATE without the tC18 purification post-radiolabeling remained stable (RCP  $\geq 95\%$  at 72h post radiolabeling, experiment 1 and 2, see Table 1).



**Figure 1.** Typical RP-HPLC radiochromatogram of  $^{177}\text{Lu}$ -DOTA-TATE

(A) with a RCP of  $>95\%$  and  $^{177}\text{Lu}$ -DOTA-TATE (B) with a RCP  $<95\%$ . Peaks (I):  $^{177}\text{Lu}$ -DOTA-TATE, (II):  $^{177}\text{Lu}$ -DTPA and  $^{177}\text{Lu}$  and (III): radiolysed fragments of  $^{177}\text{Lu}$ -DOTA-TATE. These fragments were not further characterised. X-axes are expressed in time (min) and Y-axes in mV.

After increasing the volume up to 20 mL at constant volume activity (experiments 5, Table 1),  $^{177}\text{Lu}$ -DOTA-TATE remained stable (RCP  $\geq 95\% \sim 24\text{h}$  post-radiolabeling) as shown in Fig. 2B, while the RCP of  $^{177}\text{Lu}$ -DOTA-TATE in a patient dose (7.4 GBq/100 mL) rapidly decreased below 95% within 12 h (Fig 2C, experiment 7, see Table 1).

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.